Thursday, August 03, 2023
ConcertAI's TeraRecon, a leading provider of advanced visualization and clinical AI SaaS solutions, has announced a collaboration with Mirada Medical to integrate MiradaXD, a multi-modality nuclear medicine imaging software, into TeraRecon's AI partner program. This partnership aims to provide comprehensive oncology imaging solutions and support to cancer care providers.
Mirada Medical's advanced software solutions, developed by experts in medical imaging, address various cancer-related challenges, from automating tumor segmentation and tracking to personalized treatment planning and response assessment. Their toolset streamlines workflows, enabling clinicians to efficiently and accurately identify cancerous and healthy anatomy for precise diagnosis. Additionally, physicians can easily communicate critical findings with patients' providers across the healthcare system through detailed tables, graphs, and key image exports. Mirada's versatile clinical workflows also allow quantitative PET/CT reading, hybrid PET/MR interpretation, software-based PET/MR and SPECT/MR fusion, and more.
Jon DeVries, CEO of Mirada Medical, expressed excitement about the partnership, stating, "We are thrilled to partner with TeraRecon to bring our solutions to a wider audience of cancer care providers. TeraRecon's Intuition is a highly innovative solution that perfectly complements our technology, enabling seamless integration into clinical workflows and delivering clear value to oncology patients and clinicians alike. Clinicians will also now be able to access longitudinal patient data, ultimately empowering them to offer better, personalized care."
TeraRecon's Intuition solution is a comprehensive suite of advanced visualization and clinical workflow tools, optimizing the utilization of medical imaging data across various care settings. With the integration of Mirada Medical's solutions, Intuition expands its offering, providing a more complete and personalized oncology imaging solution. This enhancement facilitates more accurate and efficient diagnosis, treatment planning, and monitoring of cancer patients.
Dan McSweeney, President, and CEO of TeraRecon shared his excitement about the collaboration, stating, "We are excited to join forces with Mirada Medical to bring the best of both companies' solutions to the market. Our shared mission is to provide innovative technologies that help improve patient outcomes and enhance clinician experience. We believe that the integration of Mirada's multi-modality imaging solutions into Intuition will be a game-changer for cancer care providers, offering a unique combination of advanced visualization and our AI-powered analytics."